Janux Therapeutics (JANX) Equity Ratio (2020 - 2025)
Historic Equity Ratio for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to 0.95.
- Janux Therapeutics' Equity Ratio rose 94.76% to 0.95 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.95, marking a year-over-year increase of 94.76%. This contributed to the annual value of 0.96 for FY2024, which is 644.02% up from last year.
- According to the latest figures from Q3 2025, Janux Therapeutics' Equity Ratio is 0.95, which was up 94.76% from 0.96 recorded in Q2 2025.
- In the past 5 years, Janux Therapeutics' Equity Ratio ranged from a high of 0.97 in Q2 2021 and a low of 0.88 during Q2 2023
- In the last 5 years, Janux Therapeutics' Equity Ratio had a median value of 0.95 in 2024 and averaged 0.93.
- In the last 5 years, Janux Therapeutics' Equity Ratio soared by 20685.02% in 2021 and then plummeted by 871.28% in 2023.
- Janux Therapeutics' Equity Ratio (Quarter) stood at 0.96 in 2021, then decreased by 8.64% to 0.88 in 2022, then rose by 2.73% to 0.91 in 2023, then rose by 6.44% to 0.96 in 2024, then fell by 1.1% to 0.95 in 2025.
- Its last three reported values are 0.95 in Q3 2025, 0.96 for Q2 2025, and 0.96 during Q1 2025.